SciSparc Ltd.
SPRC evidence brief
What we can confirm
- Market Cap:
- $117.2M
What it means
What to watch
Prepared research question
What matters most for SPRC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SPRC
SciSparc Ltd. (SPRC) is a clinical-stage pharmaceutical company focused on cannabinoid-based therapies, operating through its subsidiary NeuroThera, with programs for Tourette syndrome, Alzheimer's disease, autism spectrum disorder, and status epilepticus, and currently generates no revenue from pharmaceutical product sales [sec · filed 2026-04-29].
Key risk: Going concern doubt
Market Cap
$117.2M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
SciSparc Ltd. (SPRC) is a clinical-stage pharmaceutical company focused on cannabinoid-based therapies, operating through its subsidiary NeuroThera, with programs for Tourette syndrome, Alzheimer's disease, autism spectrum disorder, and status epilepticus, and currently generates no revenue from pharmaceutical product sales [sec · filed 2026-04-29].
- SciSparc, through its majority-owned subsidiary NeuroThera, is developing SCI-110 for Tourette syndrome and Alzheimer's disease/agitation, and SCI-210 for autism spectrum disorder and status epilepticus [sec · filed 2026-04-29].
- The company has a majority-owned subsidiary that sells hemp seed oil-based products on Amazon Marketplace [sec · filed 2026-04-29].
- In September 2025, the board approved an early-stage research initiative applying quantum computing to protein modeling and drug discovery [sec · filed 2026-04-29].
- SciSparc has a cooperation agreement with Clearmind to explore psychedelic-centric drug candidates, resulting in thirteen patent applications as of the date of the annual report [sec · filed 2026-04-29].
- The company's independent registered public accounting firm expressed substantial doubt about its ability to continue as a going concern in the audited financial statements for the period ended December 31, 2025 [sec · filed 2026-04-29].
What works
- SciSparc has a diversified pipeline targeting multiple neurological and psychiatric indications, including Tourette syndrome, Alzheimer's disease, autism spectrum disorder, and status epilepticus [sec · filed 2026-04-29].
- The company has initiated early-stage research into quantum computing for drug discovery, which could potentially enhance its modeling capabilities [sec · filed 2026-04-29].
- A cooperation agreement with Clearmind has led to thirteen patent applications, indicating active intellectual property generation [sec · filed 2026-04-29].
What to weigh
- SciSparc has incurred significant losses since inception and expects to continue doing so until it can generate revenue from product sales [sec · filed 2026-04-29].
- The company's independent auditor expressed substantial doubt about its ability to continue as a going concern, which may hinder financing efforts [sec · filed 2026-04-29].
- All pharmaceutical product candidates are in late preclinical or early clinical stages, with no pivotal studies commenced and no revenue from pharmaceutical sales [sec · filed 2026-04-29].
- The company expects to need substantial additional funding to become profitable, and failure to obtain it could force delays or termination of development efforts [sec · filed 2026-04-29].
From the filings
Quoted directly from source documents.
SciSparc's focus is on cannabinoid-based pharmaceutical development through its subsidiary NeuroThera.
“Our focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals.”
SEC filings · April 29, 2026
The company's independent auditor expressed substantial doubt about its ability to continue as a going concern.
“The report of our independent registered public accounting firm on our audited consolidated financial statements for the period ended December 31, 2025, contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern.”
SEC filings · April 29, 2026
SciSparc currently generates no revenue from pharmaceutical product sales.
“We currently generate no revenue from sales of any pharmaceutical product candidate, and we may never be able to develop or commercialize a marketable pharmaceutical product candidate.”
SEC filings · April 29, 2026
The company has a cooperation agreement with Clearmind for psychedelic-centric drug candidates.
“Our collaboration with Clearmind has resulted as of the date of this Annual Report, in the filing of thirteen patent applications.”
SEC filings · April 29, 2026
Risks & what to watch (4)›
Key risks
- Going concern doubt — Auditor expressed substantial doubt about ability to continue as a going concern as of Dec 31, 2025 [sec · filed 2026-04-29].
- No revenue from pharma — Company generates no revenue from pharmaceutical product sales and may never do so [sec · filed 2026-04-29].
- Funding dependency — Expects to need substantial additional funding; failure to obtain it could delay or terminate development [sec · filed 2026-04-29].
- Early-stage pipeline — All product candidates are in late preclinical or early clinical stages; no pivotal studies started [sec · filed 2026-04-29].
What to watch
- Progress of SCI-110 and SCI-210 through clinical development and any regulatory milestones [sec · filed 2026-04-29].
- Outcome of the quantum computing drug discovery initiative launched in September 2025 [sec · filed 2026-04-29].
- Ability to secure additional financing given the auditor's going-concern qualification [sec · filed 2026-04-29].
- Developments from the Clearmind cooperation, including any further patent filings or clinical progress [sec · filed 2026-04-29].
Sources: SEC filings · Generated October 1, 2026 · How we verify sources →
Run SciSparc Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SciSparc Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4
Total value held
$12K
| Holder | Shares | Value |
|---|---|---|
| ubs group ag | 3,146 | $12K |
| strategic investment solutions, inc. /il | 133 | $487 |
| sbi securities co., ltd. | 1 | $4 |
| rhumbline advisers | 0 | $0 |
Short Interest
as of Apr 30, 2026- % of float
- 5.5%
- Days to cover
- 2.5
- Shares short
- 30,800
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SPRC short interestFrequently asked questions
What is the AI investment thesis for SciSparc Ltd.?
SciSparc Ltd. (SPRC) is a clinical-stage pharmaceutical company focused on cannabinoid-based therapies, operating through its subsidiary NeuroThera, with programs for Tourette syndrome, Alzheimer's disease, autism spectrum disorder, and status epilepticus, and currently generates no revenue from pharmaceutical product sales [sec · filed 2026-04-29].
Who is the CEO of SciSparc Ltd.?
Mr. Oz Adler C.P.A. is the chief executive officer of SciSparc Ltd. (SPRC).
Where is SciSparc Ltd. headquartered?
SciSparc Ltd. (SPRC) is headquartered in Tel Aviv-Yafo, Israel.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.